American Century Companies Inc. Grows Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

American Century Companies Inc. grew its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 66.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,214 shares of the company's stock after acquiring an additional 4,497 shares during the period. American Century Companies Inc.'s holdings in Inspire Medical Systems were worth $2,079,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in INSP. State Street Corp increased its position in shares of Inspire Medical Systems by 78.0% during the third quarter. State Street Corp now owns 1,049,784 shares of the company's stock worth $221,557,000 after acquiring an additional 459,990 shares during the period. Geode Capital Management LLC raised its position in shares of Inspire Medical Systems by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 483,654 shares of the company's stock worth $102,102,000 after acquiring an additional 3,128 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in Inspire Medical Systems during the fourth quarter worth approximately $80,419,000. Allspring Global Investments Holdings LLC boosted its holdings in Inspire Medical Systems by 21.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 326,299 shares of the company's stock valued at $61,709,000 after purchasing an additional 58,447 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Inspire Medical Systems by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 296,207 shares of the company's stock valued at $54,911,000 after purchasing an additional 15,042 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the transaction, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at approximately $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Inspire Medical Systems Stock Up 1.7 %

INSP stock traded up $2.52 during trading on Friday, hitting $147.10. The company had a trading volume of 335,977 shares, compared to its average volume of 591,930. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40. The firm has a 50-day moving average price of $169.67 and a 200-day moving average price of $185.12. The firm has a market cap of $4.38 billion, a PE ratio of 85.03, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on INSP shares. Wells Fargo & Company reduced their price objective on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. KeyCorp reissued an "overweight" rating and issued a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Stifel Nicolaus decreased their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating for the company in a research note on Tuesday, January 21st. Robert W. Baird cut their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 11th. Finally, Morgan Stanley reduced their target price on Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Inspire Medical Systems presently has a consensus rating of "Moderate Buy" and an average target price of $226.70.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.